(Q33337294)

English

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Cladribine in combination with mitoxantrone and cyclophosphamide(CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Joanna Góra-Tybor

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Ewa Lech-Marańda

3

object named as

E Lech-Marańda

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1

object named as

T Robak

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

J Z Błoński

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

M Kasznicki

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

publication date

1 March 2001

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

66

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

188-194

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11350487%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

High complete remission rate from 2-chloro-2'-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Activity of fludarabine in previously treated non-Hodgkin's low-grade lymphoma: results of an Eastern Cooperative Oncology Group study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Activity of 2-chlorodeoxyadenosine (Cladribine) in 2-hour intravenous infusion in 94 previously treated patients with low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Key issues in the treatment of chronic lymphocytic leukaemia (CLL)

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Phase I/II study of 2-chloro-2'-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Cladribine and mitoxantrone dose escalation in indolent non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

High response rates with short infusional 2-chlorodeoxyadenosine in de novo and relapsed low-grade lymphoma. Australian and New Zealand Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Intermittent infusion of cladribine (CdA) in previously treated patients with low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

21 January 2018

2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

The influence of 2-chlorodeoxyadenosine (2-CdA) alone and in combination with cyclophosphamide or methotrexate on normal and leukemic hematopoiesis

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone and dexamethasone (CMD) in the treatment of refractory and recurrent low grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Updated Kiel classification for lymphomas

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

FMP regimen (fludarabine, mitoxantrone, prednisone) as therapy in recurrent low‐grade non‐Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0609.2001.00303.X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33337294&oldid=2118185119"